Differential Reponses of Hematopoietic Stem and Progenitor Cells to mTOR Inhibition

Stem Cells International

Volumn 2015, Issue , 2015, Pages

  Yang, Aimin ^a   Xiao, Xia ^a,b   Zhao, Mingfeng ^b   LaRue, Amanda C ^a,c,d   Schulte, Bradley A ^a   Wang, Gavin Y ^a,d  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b TIANJIN FIRST CENTRAL HOSPITAL   (China)

^c RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 [2 (2,6 DIMETHYLMORPHOLINO) 4 MORPHOLINOPYRIDO[2,3 D]PYRIMIDIN 7 YL] 2 METHOXYBENZENEMETHANOL; AZD 8055; CASPASE 3; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; S6 KINASE; THROMBOPOIETIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL SURVIVAL; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; GROWTH INHIBITION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

MAMMALIA;

EID: 84937010798     PISSN: None     EISSN: 16879678     Source Type: Journal    
DOI: 10.1155/2015/561404     Document Type: Article

References (31)

1. M. Laplante and D. M. Sabatini, "mTOR signaling in growth control and disease, " Cell, vol. 149, no. 2, pp. 274-293, 2012.
2. T.Hoshii, S.Matsuda, and A.Hirao, "Pleiotropic roles ofmTOR complexes in haemato-lymphopoiesis and leukemogenesis, " The Journal of Biochemistry, vol. 156, no. 2, pp. 73-83, 2014.
3. E. Jacinto, R. Loewith, A. Schmidt et al., "Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive, " Nature Cell Biology, vol. 6, no. 11, pp. 1122-1128, 2004.
4. J. M. García-Martínez, J. Moran, R. G. Clarke et al., "Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR), " Biochemical Journal, vol. 421, no. 1, pp. 29-42, 2009.
5. D. D. Sarbassov, D. A. Guertin, S. M. Ali, and D. M. Sabatini, "Phosphorylation and regulation of Akt/PKB by the rictormTOR complex, " Science, vol. 307, no. 5712, pp. 1098-1101, 2005.
6. B. M. Slomovitz and R. L. Coleman, "The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer, " Clinical Cancer Research, vol. 18, no. 21, pp. 5856-5864, 2012.
7. Ö. H. Yilmaz, R. Valdez, B. K. Theisen et al., "Pten dependence distinguishes haematopoietic stem cells fromleukaemiainitiating cells, " Nature, vol. 441, no. 7092, pp. 475-482, 2006.
8. N. A. O'Brien, K. McDonald, L. Tong et al., "Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT, " Clinical Cancer Research, vol. 20, no. 13, pp. 3507-3520, 2014.
9. F. Janku, J. J. Wheler, S. N. Westin et al., "PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CAmutations, " Journal of ClinicalOncology, vol. 30, no. 8, pp. 777-782, 2012.
10. J. A. Magee, T. Ikenoue, D. Nakada, J. Y. Lee, K.-L. Guan, and S. J. Morrison, "Temporal changes in PTEN and mTORC2 regulation of hematopoietic stem cell self-renewal and leukemia suppression, " Cell Stem Cell, vol. 11, no. 3, pp. 415-428, 2012.
11. A. Gutierrez, T. Sanda, R. Grebliunaite et al., "High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia, " Blood, vol. 114, no. 3, pp. 647-650, 2009.
12. K. Tanaka, I. Babic, D. Nathanson et al., "Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance, " Cancer Discovery, vol. 1, no. 6, pp. 524-538, 2011.
13. X. Xiao, H. Luo, K. N. Vanek, A. C. LaRue, B. A. Schulte, and G. Y. Wang, "Catalase inhibits ionizing radiation-induced apoptosis in hematopoietic stem and progenitor cells, " Stem Cells and Development, vol. 24, no. 11, pp. 1342-1351, 2015.
14. Y.Wang, B. A. Schulte, A. C. LaRue, M. Ogawa, and D. Zhou, "Total body irradiation selectively induces murine hematopoietic stem cell senescence, " Blood, vol. 107, no. 1, pp. 358-366, 2006.
15. Y. Wang, J. Kellner, L. Liu, and D. Zhou, "Inhibition of p38 mitogen-activated protein kinase promotes ex vivo hematopoietic stem cell expansion, " Stem Cells and Development, vol. 20, no. 7, pp. 1143-1152, 2011.
16. S. A. Kang, M. E. Pacold, C. L. Cervantes et al., "mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin, " Science, vol. 341, no. 6144, Article ID1236566, 2013.
17. C. Récher, O. Beyne-Rauzy, C. Demur et al., "Antileukemic activity of rapamycin in acute myeloid leukemia, " Blood, vol. 105, no. 6, pp. 2527-2534, 2005.
18. L. Ciuffreda, C. di Sanza, U. C. Incani, and M. Milella, "The mTOR pathway: a new target in cancer therapy, " Current Cancer Drug Targets, vol. 10, no. 5, pp. 484-495, 2010.
19. A. E. Perl, M. T. Kasner, D. E. Tsai et al., "Aphase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia, " Clinical Cancer Research, vol. 15, no. 21, pp. 6732-6739, 2009.
20. S. M. Guichard, Z. Howard, D. Heathcote et al., "AZD2014, a dual mTORC1 and mTORC2 inhibitor is differentiated from allosteric inhibitors of mTORC1 in ER+ breast cancer, " in Proceedings of the 103rd AACR Annual Meeting, vol. 72, p. 917, Chicago, Ill, USA, April 2012.
21. C. García-Echeverría, "Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment, " Bioorganic and Medicinal Chemistry Letters, vol. 20, no. 15, pp. 4308-4312, 2010.
22. D. Benjamin, M. Colombi, C. Moroni, and M. N. Hall, "Rapamycin passes the torch: a new generation of mTOR inhibitors, " Nature Reviews Drug Discovery, vol. 10, no. 11, pp. 868-880, 2011.
23. A. Naing, C. Aghajanian, E. Raymond et al., "Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma, " British Journal of Cancer, vol. 107, no. 7, pp. 1093-1099, 2012.
24. C. M. Chresta, B. R. Davies, I. Hickson et al., "AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity, " Cancer Research, vol. 70, no. 1, pp. 288-298, 2010.
25. Z.-J. Liu, J. Italiano Jr., F. Ferrer-Marin et al., "Developmental differences in megakaryocytopoiesis are associated with upregulated TPO signaling through mTOR and elevated GATA-1 levels in neonatal megakaryocytes, " Blood, vol. 117, no. 15, pp. 4106-4117, 2011.
26. A. L. Drayer, S. G. M. Olthof, and E. Vellenga, "Mammalian target of rapamycin is required for thrombopoietin-induced proliferation ofmegakaryocyte progenitors, " Stem Cells, vol. 24, no. 1, pp. 105-114, 2006.
27. D. Kalaitzidis, S. M. Sykes, Z. Wang et al., "mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis, " Cell Stem Cell, vol. 11, no. 3, pp. 429-439, 2012.
28. F. Guo, S. Zhang, M. Grogg et al., "Mouse gene targeting reveals an essential role of mTOR in hematopoietic stem cell engraftment and hematopoiesis, " Haematologica, vol. 98, no. 9, pp. 1353-1358, 2013.
29. Y. Luo, L. Li, P. Zou et al., "Rapamycin enhances longterm hematopoietic reconstitution of ex vivo expanded mouse hematopoietic stem cells by inhibiting senescence, " Transplantation, vol. 97, no. 1, pp. 20-29, 2014.
30. J. Huang, M. Nguyen-Mccarty, E. O. Hexner, G. Danet-Desnoyers, and P. S. Klein, "Maintenance of hematopoietic stem cells through regulation of Wnt and mTOR pathways, " Nature Medicine, vol. 18, no. 12, pp. 1778-1785, 2012.
31. L. Willems, N. Chapuis, A. Puissant et al., "The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acutemyeloid leukemia, " Leukemia, vol. 26, no. 6, pp. 1195-1202, 2012.